Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Ovulation Inducing Drugs Market Expected To Grow In Terms Of Size?

In recent times, the ovulation inducing drugs market has witnessed significant growth. Its value is forecasted to rise from $4.42 billion in 2024 to $4.7 billion in 2025, showing a compound annual growth rate (CAGR) of 6.5%. The strong growth experienced in the previous period can be credited to various factors such as the development of clomiphene citrate, the launch of letrozole, the approval and standardization by regulators, as well as the advent of ovulation predictor kits.

Anticipations are high for the ovulation inducing drugs market, as it is predicted to experience significant expansion in the coming years. The market is projected to increase to $6.11 billion in 2029, boasting a compound annual growth rate (CAGR) of 6.8%. This expected surge within the forecast period could be a result of various factors such as lifestyle changes, postponement of childbirth, the inclusion of digital health, an increasingly widespread market, escalating infertility rates, as well as individualized treatment programs. Key trends to be cognizant of during this forecast period involve tailor-made treatment methods, improvements in reproductive endocrinology, non-intrusive fertility tracking, a growing call for assisted reproductive technologies, and the creation of innovative drug formulations.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

Which Growth Drivers Are Shaping The Ovulation Inducing Drugs Market Outlook?

The rise in women’s infertility is anticipated to drive the expansion of the ovulation-inducing drug market. The inability of a woman to get pregnant or maintain a pregnancy to full term despite regular unprotected sex over a long span, usually a year or more, is referred to as women’s infertility. Ovulation-inducing medications are utilized for the treatment of this issue, particularly when ovulation is inconsistent or non-existent. These drugs aim at the hormonal pathways that are part of the ovulation process and encourage the ovaries to release mature eggs. The Centers for Disease Control and Prevention, a US government agency, has predicted that in 2022, about 6.1 million women aged between 15 and 44 will face difficulties in conceiving in the US, accounting for 10% of all women. Moreover, according to CCRM Management Company LLC, a US medical management firm, in June 2022, 1 in every 4 couples around the world would be affected by infertility, increasing by 5% to 10% annually. Thus, the escalating rates of women’s infertility is bolstering the growth of the ovulation-inducing drug market.

Which Segment Accounts For The Largest Share In The Ovulation Inducing Drugs Market?

The ovulation inducing drugs market covered in this report is segmented –

1) By Drug Class: Hormones, Therapeutics Drugs

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors

2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine

Which Long-Term Trends Will Play A Crucial Role In The Ovulation Inducing Drugs Market?

Major businesses in the ovulation-inducing drug market focus on the production of innovative medications such as Cetrorelix acetate, getting them approved to aid women who are undergoing controlled ovarian stimulation. Cetrorelix acetate, a supplementary injection, works as an antagonist to the gonadotropin-releasing hormone (GnRH). It is essential in preventing premature ovulation in women undergoing in vitro fertilization (IVF). For example, in August 2022, the US-based pharmaceutical organization, Akorn Operating Company LLC, achieved FDA approval for a generic iteration of Cetrorelix acetate for injection, rated at 0.25 mg (Cetrorelix). This marks the first AP-rated bioequivalent to the initial Merck Serono Cetrotide version that has been granted authorization. Cetrorelix acetate operates as a GnRH antagonist that nullifies the impacts of the gonadotropin-releasing hormone (GnRH). GnRH, then, encourages the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Additionally, it is applied to prevent premature LH surges during controlled ovarian stimulation (COS) and ensures the maturation of all eggs.

Who Are The Dominant Players In The Ovulation Inducing Drugs Market Today?

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

What Regional Factors Are Accelerating Growth In The Ovulation Inducing Drugs Market?

North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13256&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model